BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Immix Biopharma (IMMX)Immix BiopharmaCompany update

LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received a strategic investment from Goose Capital and former Tanox, Inc. CEO Dr. Nancy T. Chang,...

Related news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

BMYBMYBristol-Myers Squibb Company2026-08-10 13:01 EST

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-08-04 14:15 EST

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

IMMXImmix Biopharma2026-05-22 22:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-22 17:15 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-05-21 11:30 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

Stock data

Close
13.66 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States